NLS Pharmaceutics to Participate in Upcoming Investor Conferences
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, is pleased to announce its participation in the following upcoming conferences:
瑞士秀克黎世/ACCESSWIRE/2023年1月11日/亞洲網加利福尼亞州聖約瑟10月31日電瑞士臨床階段生物製藥公司NLS製藥有限公司(納斯達克市場代碼：NLSP，NLSPW)(以下簡稱“公司”)今天高興地宣佈，它將參加即將召開的下列會議：
- 2023 BIO CEO & Investor Conference
- 2023年BIO首席執行官和投資者大會
Alex Zwyer, NLS' Chief Executive Officer, will present a company update at the 2023 BIO CEO & Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system:
NLS首席執行官Alex Zwyer將在2023年3月12日至14日舉行的2023年BIO CEO和投資者會議上介紹公司最新情況，並將與與會者進行一對一的會議。那些有興趣安排會議的人可以通過Bio一對一合作系統來實現：
- 35th Annual Roth Conference
- 第35屆Roth年會
Alex Zwyer, NLS' Chief Executive Officer, will participate in and host investor meetings at the 35th Annual Roth Conference on March 12-14, 2023.If you plan on attending the conference, please reach out to your ROTH representative to request a meeting.
NLS首席執行官Alex Zwyer將參加2023年3月12日至14日舉行的第35屆Roth年會並主持投資者會議。如果您計劃參加會議，請聯繫您的Roth代表請求會面。
About NLS Pharmaceutics Ltd.
關於NLS製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS製藥有限公司(納斯達克代碼：NLSP)是一家全球開發期生物製藥公司，與世界級合作夥伴和國際公認的科學家網絡合作，專注於為患有罕見和複雜的中樞神經系統疾病的患者發現和開發創新療法，這些患者的醫療需求尚未得到滿足。NLS總部設在瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，該團隊在開發和商業化候選產品方面有著良好的記錄。欲瞭解更多資訊，請訪問。
For additional information:
有關更多資訊，請訪問：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投資者和媒體)
NLS製藥有限公司。
+1 239.682.8500
郵箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
資料來源：NLS製藥公司